Transforming growth factor-beta (TGF-β), a well-known morphogen, is recognized for its role in regulating growth and ...

For the first time, researchers have discovered that the accumulation of aged and failing cells, called senescent cells, in ...

TCGFB is paying Surrozen up to $6 million, plus any third-party costs, for antibodies that target transforming growth factor beta (TGF-Beta). Dysfunctional TGF-Beta is a major contributor to lung ...

Surrozen (SRZN) announced a strategic research collaboration with privately-held TCGFB to discover antibody therapeutics targeting Transforming ...

Inc. is a clinical-stage biopharmaceutical company that specializes in developing and commercializing novel therapeutics for treating disorders related to dysfunctional signaling of the transforming ...

Detailed price information for Keros Therapeutics Inc (KROS-Q) from The Globe and Mail including charting and trades.

Detailed price information for Keros Therapeutics Inc (KROS-Q) from The Globe and Mail including charting and trades.

Scholar Rock (NASDAQ: SRRK; the "Company"), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy, cardiometabolic disorders, and other serious ...

Endothelial cells are also likely to participate in activation, both by production of cellular fibronectin and via conversion of transforming growth factor (TGF)-beta from the latent to active ...

Understanding LDS is crucial for early diagnosis and management, which can significantly improve the quality of life for ...